These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31806078)

  • 1. Vinorelbine in Non-Small Cell Lung Cancer: Real-World Data From a Single-Institution Experience.
    Nobili S; Lavacchi D; Perrone G; Vicini G; Tassi R; Landini I; Grosso A; Roviello G; Mazzanti R; Santomaggio C; Mini E
    Oncol Res; 2020 May; 28(3):237-248. PubMed ID: 31806078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.
    Yue D; Xu S; Wang Q; Li X; Shen Y; Zhao H; Chen C; Mao W; Liu W; Liu J; Zhang L; Ma H; Li Q; Yang Y; Liu Y; Chen H; Wang C
    Lancet Respir Med; 2018 Nov; 6(11):863-873. PubMed ID: 30150014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
    Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
    Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metronomic Chemotherapy with Vinorelbine Produces Clinical Benefit and Low Toxicity in Frail Elderly Patients Affected by Advanced Non-Small Cell Lung Cancer.
    D'Ascanio M; Pezzuto A; Fiorentino C; Sposato B; Bruno P; Grieco A; Mancini R; Ricci A
    Biomed Res Int; 2018; 2018():6278403. PubMed ID: 30225260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer.
    Ouyang X; Shi M; Jie F; Bai Y; Shen P; Yu Z; Wang X; Huang C; Tao M; Wang Z; Xie C; Wu Q; Shu Y; Han B; Zhang F; Zhang Y; Hu C; Ma X; Liang Y; Wang A; Lu B; Shi Y; Chen J; Zhuang Z; Wang J; Huang J; Wang C; Bai C; Zhou X; Li Q; Chen F; Yu H; Feng J
    Invest New Drugs; 2018 Apr; 36(2):315-322. PubMed ID: 29134432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I-II study of paclitaxel, ifosfamide, and vinorelbine with filgrastim (rhG-CSF) support in advanced non-small-cell lung cancer.
    Masters GA; Mauer AM; Hoffman PC; Wyka D; Samuels BL; Krauss SA; Watson S; Golomb H; Vokes EE
    Ann Oncol; 1998 Jun; 9(6):677-80. PubMed ID: 9681085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial.
    Platania M; Pasini F; Porcu L; Boeri M; Verderame F; Modena Y; Del Conte A; Nichetti F; Garassino MC; Martinetti A; Sottotetti E; Cavanna L; Vattemi E; Pozzessere D; Bertolini A; Irtelli L; Verri C; Sozzi G; Proto C; Pastorino U; Torri V; Fraccon AP; Spinnato F; Signorelli D; Lo Russo G; Tuzi A; Gallucci R; Cinieri S; Mencoboni M; Antonelli P; Giacomelli L; de Braud F
    Lung Cancer; 2019 Jun; 132():17-23. PubMed ID: 31097088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Oral vinorelbine: pharmacology and treatment outcome in non-small cell bronchial carcinoma and breast carcinoma].
    Bartsch V
    Onkologie; 2006 Mar; 29 Suppl 1():1-28. PubMed ID: 16534241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metronomic oral vinorelbine for the treatment of advanced non-small cell lung cancer: a multicenter international retrospective analysis.
    Camerini A; Banna GL; Cinieri S; Pezzuto A; Mencoboni M; Rosetti F; Figueiredo A; Rizzo P; Ricci A; Langenhoven L; Santo A; Addeo A; Amoroso D; Barata F
    Clin Transl Oncol; 2019 Jun; 21(6):790-795. PubMed ID: 30448956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and toxicity of metronomic oral vinorelbine monotherapy in patients with non-small cell lung cancer: a meta-analysis.
    Xu K; Liu T; Zhang J; Zhou Y; Yang F; Ren T
    Int J Clin Oncol; 2020 Sep; 25(9):1624-1634. PubMed ID: 32472208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes of oral metronomic vinorelbine in advanced non-small cell lung cancer: correlations with pharmacokinetics and MDR1 polymorphisms.
    Gusella M; Pasini F; Caruso D; Barile C; Modena Y; Fraccon AP; Bertolaso L; Menon D; Crepaldi G; Bononi A; Spezzano R; Telatin GA; Corona G; Padrini R
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):493-500. PubMed ID: 30542768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study.
    Rusu P; Ciuleanu TE; Cernea D; Pelau D; Gaal V; Cebotaru C; Guttman T; Todor N; Ghilezan N
    J BUON; 2007; 12(1):33-9. PubMed ID: 17436399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metronomic Oral Vinorelbine: An Alternative Schedule in Elderly and Patients PS2 With Local/Advanced and Metastatic NSCLC Not Oncogene-addicted.
    Rossi D; Lippe P; Rocchi MBL; Sarti D; Catalano V; Graziano F; Giordani P; Baldelli A; Fedeli SL; Imperatori L; Laici G; Cappelletti C; Tamburrano T; Bracci R; Alessandroni P
    In Vivo; 2020; 34(5):2687-2691. PubMed ID: 32871800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV non-small-cell lung cancer: a prospective randomized study of the Southern Italy Oncology Group (GOIM).
    Colucci G; Gebbia V; Galetta D; Riccardi F; Cariello S; Gebbia N
    Br J Cancer; 1997; 76(11):1509-17. PubMed ID: 9400950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vinorelbine and carboplatin in inoperable non-small cell lung cancer: a monoinstitutional phase II study.
    Cremonesi M; Mandalà M; Cazzaniga M; Rezzani C; Gambera M; Barni S
    Oncology; 2003; 64(2):97-101. PubMed ID: 12566905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vinorelbine in combination with carboplatin followed by single-agent consolidation therapy for unresectable localized or metastatic non-small-cell lung carcinomas.
    Alici S; Coskun U; Alkis N; Sevinc A; Dane F; Gumus M; Ozkan M; Kaya AO; Celenkoglu G; Buyukberber S; Altunbas M; Benekli M;
    Asian Pac J Cancer Prev; 2009; 10(6):1051-5. PubMed ID: 20192582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ifosfamide and vinorelbine as first-line chemotherapy for advanced non-small cell lung carcinoma.
    Vallejo C; Romero A; Perez J; Cuevas M; Lacava J; Sabatini C; Dominguez M; Rodriguez R; Barbieri M; Romero Acuña L; Romero Acuña J; Langhi M; Amato S; Salvadori M; Ortiz E; Machiavelli M; Leone B
    Am J Clin Oncol; 1996 Dec; 19(6):584-8. PubMed ID: 8931677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.
    Reck M; Macha HN; Del Barco S; Cornes P; Vaissière N; Morand M; Riggi M; Abratt R
    Lung Cancer; 2009 Jun; 64(3):319-25. PubMed ID: 19095327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer.
    Pujol JL; Coffy A; Camerini A; Kotsakis A; Mencoboni M; Gusella M; Pasini F; Pezzuto A; Banna GL; Bilir C; Samantas E; Barlesi F; Roch B; Guillou A; Daurès JP
    PLoS One; 2019; 14(8):e0220988. PubMed ID: 31430345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of vinorelbine plus carboplatin with concurrent radiotherapy in elderly patients with non-small cell lung cancer.
    Yamaguchi M; Hirata H; Ebi N; Araki J; Seto T; Maruyama R; Akamine S; Inoue Y; Semba H; Sasaki J; Okamoto T
    Jpn J Clin Oncol; 2020 Mar; 50(3):318-324. PubMed ID: 31804689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.